Merus (MRUS) Projected to Post Quarterly Earnings on Thursday

Key Points

• Merus (MRUS) is scheduled to announce its Q1 2025 earnings on August 7th, with an expected loss of ($1.17) per share.
• The biotechnology company's previous earnings report missed expectations, showing a loss of ($1.40) per share despite revenues of $26.49 million.
• Insider selling has occurred recently, with COO Peter B. Silverman selling 25,000 shares for $1,500,000, while institutional investors own 96.14% of the company's stock.

Merus (NASDAQ:MRUS - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($1.17) per share for the quarter.

Merus (NASDAQ:MRUS - Get Free Report) last posted its earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). The business had revenue of $26.49 million for the quarter, compared to analyst estimates of $7.82 million. Merus had a negative net margin of 506.73% and a negative return on equity of 35.99%. On average, analysts expect Merus to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Merus Price Performance

MRUS traded down $0.68 during midday trading on Friday, hitting $65.56. 664,677 shares of the company were exchanged, compared to its average volume of 679,176. The company's 50 day simple moving average is $56.89 and its 200 day simple moving average is $47.76. Merus has a 1-year low of $33.19 and a 1-year high of $67.59.

Analysts Set New Price Targets

MRUS has been the subject of a number of analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $75.00 price target on shares of Merus in a report on Monday, May 19th. William Blair reissued an "outperform" rating on shares of Merus in a report on Monday, April 28th. Wells Fargo & Company cut their price objective on shares of Merus from $91.00 to $89.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. BMO Capital Markets set a $110.00 target price on shares of Merus and gave the stock an "outperform" rating in a research note on Friday, May 23rd. Finally, Wall Street Zen lowered Merus from a "hold" rating to a "sell" rating in a research note on Sunday, July 20th. One equities research analyst has rated the stock with a sell rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $86.40.

Insider Transactions at Merus

In other Merus news, COO Peter B. Silverman sold 25,000 shares of the stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $60.00, for a total transaction of $1,500,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders sold 82,500 shares of company stock valued at $4,586,340. Insiders own 4.57% of the company's stock.

Institutional Trading of Merus

A hedge fund recently raised its stake in Merus stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Merus N.V. (NASDAQ:MRUS - Free Report) by 14.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,522 shares of the biotechnology company's stock after purchasing an additional 13,778 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.16% of Merus worth $4,736,000 as of its most recent SEC filing. 96.14% of the stock is currently owned by institutional investors.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.